- Yale Gynecologic OncologySmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
- Yale Gynecologic OncologyStamford Hospital1 Hospital PlazaStamford, CT 06902
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
Mitchell Clark, MD, MPH
Biography
Mitchell Clark, MD, is a gynecologic oncologist with training in both surgical and medical oncology. He has expertise in chemotherapy, targeted therapies, and minimally invasive surgeries. He sees women with gynecologic malignancies and complex surgical problems, as well as genetic conditions that put them at risk for developing a gynecologic cancer.
Dr. Clark grew up in a small, rural community, where he began thinking about becoming a doctor after a close family member died from ovarian cancer. “I saw the lack of resources and advanced treatment options, and limitations in the system,” he says. “I was inspired to pursue a specialty where I could advocate for women to receive the highest quality of care close to home.”
Since then he’s seen improvements in both treatments and survival rates for women with gynecologic cancers. Surgery has evolved to the point where he can usually offer a minimally invasive approach that not only treats cancer, but also allows patients to return to their normal routines “faster than ever,” he says. “Being at Yale allows me to offer comprehensive cancer care that encompasses a multidisciplinary approach spanning from early detection to survivorship.”
In addition to caring for patients, Dr. Clark is interested in improving care for his patients through research. “I am passionate about leveraging the power of large health care administrative databases that include thousands of women to try and answer the important questions facing our specialty,” he says. Another interest is early detection and prevention of cervical cancer. “We know that most cervical cancers are due to human papillomavirus [HPV] infections, which can be prevented through vaccination,” Dr. Clark says.
Titles
- Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences
- Assistant Program Director, Minimally Invasive Gynecological Surgery Program
- Associate Director, Center for Precision Diagnosis of Trophoblastic Disease
- Director, Gynecologic Oncology at Waterford, Smilow Cancer Hospital Waterford Care Center
Education & Training
- MPHUniversity of Massachusetts (2023)
- FellowUniversity of Toronto (2020)
- ResidentYale University Bridgeport Hospital (2017)
- MDAUC School of Medicine
- BScSt. Francis Xavier University, Biology (2009)
Languages Spoken
- English
- Français (French)
Additional Information
- Early Career Investigator: NRG Oncology (2021)
- Best Oral Presentation, Annual Research Day: Department of Obstetrics and Gynecology, University of Toronto (2019)
- Best Poster Presentation, Annual General Meeting: The Society of Gynecologic Oncology of Canada (2018)
- Award for Excellence in Female Pelvic Medicine and Reconstructive Surgery: American Urogynecologic Society (2017)
- Excellence in Minimally Invasive Gynecology in Residency: American Association of of Gynecologic Laparoscopists (2017)
- Medical Student Educator of the Year: Yale University School of Medicine (2017)
- Travel and Education Grant: Society of Laparoendoscopic Surgeons (2016)
- Medical Student Educator of the Year: Yale School of Medicine (2015)
- Dr. Asudulla-Bibijan Award for Excellence in Undergraduate Research: St. Francis Xavier University (2009)
- Young Researcher Award: Canadian Breast Cancer Foundation (2007)
- Royal College of Physicians & Surgeons of CANADA, Gynecologic Oncology (2020)
- Royal College of Physicians & Surgeons of CANADA, Obstetrics & Gynecology (2018)
- Yale New Haven Healthy Lawrence and Memorial Hospital (2023 - Present): Physician Advisory Council
- Frontiers in Oncology (2023 - Present): Editor
- Connecticut Department of Health (2023 - Present): CT Cancer Partnership's HPV workgroup
- Insider (2022 - Present): https://www.insider.com/uterine-cancer-researchers-obgyn-want-more-data-on-hair-straightener-chemicals-2022-12
- Department of OBGYN Diversity, Equity and Inclusion, Research and Recruitment (2022 - Present): Co-Chair
- Yale University School of Medicine (2022 - Present): Medical Education Committee
- Medical Education Committee (2022 - Present): Member
- Diversity, Equity and Inclusion Committee of the Society of Gynecologic Oncology (2021 - Present): Committee Member
- Society of Gynecologic Oncologists of Canada (2017 - Present): Member
- American Association of Gynecologic Laparoscopists (2014 - Present): Member
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Britton M, Izampuye E, Clark M, Ornstein R, Nunez-Smith M, Wright J, Xu X. Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study. Gynecologic Oncology 2024, 191: 67-73. PMID: 39362045, DOI: 10.1016/j.ygyno.2024.09.010.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. DOI: 10.1038/s44276-024-00067-5.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLOS ONE 2023, 18: e0289692. PMID: 37682914, PMCID: PMC10490884, DOI: 10.1371/journal.pone.0289692.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- Maurer J, Ramani S, Xu B, Gallousis S, Clark M, Andikyan V. Delayed presentation of placenta accreta following a first‐trimester medical abortion. Clinical Case Reports 2023, 11: e7849. PMID: 37636882, PMCID: PMC10457480, DOI: 10.1002/ccr3.7849.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- Sullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.
- Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Ramani S, Hartnett J, Karki S, Gallousis S, Clark M, Andikyan V. Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2023, 27: e2023.00021. PMID: 37663433, PMCID: PMC10473183, DOI: 10.4293/jsls.2023.00021.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology 2022, 167: 417-422. PMID: 37191644, DOI: 10.1016/j.ygyno.2022.10.014.
- Piedimonte S, Kim S, Clark M, Lheureux S, May T, Bernardini M, Atenafu E. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190). Gynecologic Oncology 2022, 166: s109. DOI: 10.1016/s0090-8258(22)01417-2.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
- Clark M, Tchrakian N, Clarke B, Metser U, Bouchard-Fortier G. Placenta increta mimicking placental site trophoblastic tumor. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2021, 31: 1481-1485. PMID: 34725244, DOI: 10.1136/ijgc-2021-002988.
- Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Preventive Medicine 2021, 150: 106641. PMID: 34048822, DOI: 10.1016/j.ypmed.2021.106641.
- Irshaid L, Clark M, Fadare O, Finberg KE, Parkash V. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review. International Journal Of Gynecological Pathology 2021, 41: 258-267. PMID: 33990091, DOI: 10.1097/pgp.0000000000000792.
- Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
- Clark M, Jembere N, Wang L, Kupets R. Survival of Older Women With Cervical Cancer Based on Screening History. Journal Of Lower Genital Tract Disease 2021, 25: 9-14. PMID: 33347044, DOI: 10.1097/lgt.0000000000000582.
- The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital wartsClark M, Jembere N, Kupets R. The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital warts. Gynecologic Oncology 2020, 159: 173. DOI: 10.1016/j.ygyno.2020.05.257.
- Clark M, Al houssan L, Liu Z, Bernardini M. Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer. Gynecologic Oncology 2019, 154: 261. DOI: 10.1016/j.ygyno.2019.04.603.
- Clark M, Kollara A, May T, Brown T. Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperature. Gynecologic Oncology 2019, 154: 55-56. DOI: 10.1016/j.ygyno.2019.04.133.
- Clark M, Lee A, Kupets R. Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing? Journal Of Obstetrics And Gynaecology Canada 2019, 41: 1410-1415. PMID: 30803876, DOI: 10.1016/j.jogc.2018.11.034.
- Seifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: e2019.00021. PMID: 31285650, PMCID: PMC6596444, DOI: 10.4293/jsls.2019.00021.
- Seifi F, Clark M, Menderes G, Silasi D, Azodi M. 500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy? Journal Of Minimally Invasive Gynecology 2018, 25: s175. DOI: 10.1016/j.jmig.2018.09.512.
- Clark M, Seifi F, Parkash V, Silasi D, Azodi M. Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy? Gynecologic Oncology 2018, 149: 93. DOI: 10.1016/j.ygyno.2018.04.213.
- Clark M, Lee Y, Xu W, Brown T, May T. Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer? Gynecologic Oncology 2018, 149: 92. DOI: 10.1016/j.ygyno.2018.04.210.
- Lee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.
- Lennox G, Clark M, Zigras T, Rouzbahman M, Han G, Bernardini M, Gien L. Clinical stage II endometrial cancer: Is there a benefit to radical hysterectomy? Gynecologic Oncology 2018, 149: 103. DOI: 10.1016/j.ygyno.2018.04.239.
- Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reachClark M, Lee A, Kupets R. Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reach. Gynecologic Oncology 2018, 149: 126-127. DOI: 10.1016/j.ygyno.2018.04.292.
- Seifi F, Davis M, Clark M, Paraiso E, Azodi M. 563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2017, 24: s184-s185. DOI: 10.1016/j.jmig.2017.08.591.
- Seifi F, Clark M, Sami A, Azodi M. 519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction. Journal Of Minimally Invasive Gynecology 2017, 24: s183. DOI: 10.1016/j.jmig.2017.08.547.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Clark M, Menderes G, Azodi M, Finberg K, Canosa S, Parkash V. Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome. Gynecologic Oncology 2016, 141: 183-184. DOI: 10.1016/j.ygyno.2016.04.473.
- Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi D. Uterine Serous Carcinoma: Does surgical approach impact survival? Gynecologic Oncology 2015, 139: 592. DOI: 10.1016/j.ygyno.2015.09.045.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA. Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? Journal Of Minimally Invasive Gynecology 2015, 22: s48-s49. PMID: 27679256, DOI: 10.1016/j.jmig.2015.08.134.
- Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M. Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma. Journal Of Minimally Invasive Gynecology 2015, 22: s59. PMID: 27679285, DOI: 10.1016/j.jmig.2015.08.157.
- Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian CystsClark M, Zigras T, Bayat L, Kashani S. Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian Cysts. Journal Of Minimally Invasive Gynecology 2015, 22: s150. PMID: 27678844, DOI: 10.1016/j.jmig.2015.08.547.
- Donat L, Clark M, Tower AM, Menderes G, Parkash V, Silasi DA, Azodi M. Transvaginal Morcellation. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2014.00255. PMID: 26005318, PMCID: PMC4432719, DOI: 10.4293/jsls.2014.00255.
- O’Sullivan R, Sauer C, Friedman P, Clark M, Menderes G. Rupture of the Unscarred Gravid Uterus: Case Series. Journal Of Medical Cases 2015, 6: 330-332. DOI: 10.14740/jmc2203w.
- Clark L, Clark M, Menderes G, Silasi D, Azodi M. Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2014, 21: s205. DOI: 10.1016/j.jmig.2014.08.658.
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Yale Cancer Center
- Yale Gynecologic OncologySmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
- Yale Gynecologic OncologyStamford Hospital1 Hospital PlazaStamford, CT 06902
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
Biography
Mitchell Clark, MD, is a gynecologic oncologist with training in both surgical and medical oncology. He has expertise in chemotherapy, targeted therapies, and minimally invasive surgeries. He sees women with gynecologic malignancies and complex surgical problems, as well as genetic conditions that put them at risk for developing a gynecologic cancer.
Dr. Clark grew up in a small, rural community, where he began thinking about becoming a doctor after a close family member died from ovarian cancer. “I saw the lack of resources and advanced treatment options, and limitations in the system,” he says. “I was inspired to pursue a specialty where I could advocate for women to receive the highest quality of care close to home.”
Since then he’s seen improvements in both treatments and survival rates for women with gynecologic cancers. Surgery has evolved to the point where he can usually offer a minimally invasive approach that not only treats cancer, but also allows patients to return to their normal routines “faster than ever,” he says. “Being at Yale allows me to offer comprehensive cancer care that encompasses a multidisciplinary approach spanning from early detection to survivorship.”
In addition to caring for patients, Dr. Clark is interested in improving care for his patients through research. “I am passionate about leveraging the power of large health care administrative databases that include thousands of women to try and answer the important questions facing our specialty,” he says. Another interest is early detection and prevention of cervical cancer. “We know that most cervical cancers are due to human papillomavirus [HPV] infections, which can be prevented through vaccination,” Dr. Clark says.
Titles
- Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences
- Assistant Program Director, Minimally Invasive Gynecological Surgery Program
- Associate Director, Center for Precision Diagnosis of Trophoblastic Disease
- Director, Gynecologic Oncology at Waterford, Smilow Cancer Hospital Waterford Care Center
Education & Training
- MPHUniversity of Massachusetts (2023)
- FellowUniversity of Toronto (2020)
- ResidentYale University Bridgeport Hospital (2017)
- MDAUC School of Medicine
- BScSt. Francis Xavier University, Biology (2009)
Languages Spoken
- English
- Français (French)
Additional Information
- Early Career Investigator: NRG Oncology (2021)
- Best Oral Presentation, Annual Research Day: Department of Obstetrics and Gynecology, University of Toronto (2019)
- Best Poster Presentation, Annual General Meeting: The Society of Gynecologic Oncology of Canada (2018)
- Award for Excellence in Female Pelvic Medicine and Reconstructive Surgery: American Urogynecologic Society (2017)
- Excellence in Minimally Invasive Gynecology in Residency: American Association of of Gynecologic Laparoscopists (2017)
- Medical Student Educator of the Year: Yale University School of Medicine (2017)
- Travel and Education Grant: Society of Laparoendoscopic Surgeons (2016)
- Medical Student Educator of the Year: Yale School of Medicine (2015)
- Dr. Asudulla-Bibijan Award for Excellence in Undergraduate Research: St. Francis Xavier University (2009)
- Young Researcher Award: Canadian Breast Cancer Foundation (2007)
- Royal College of Physicians & Surgeons of CANADA, Gynecologic Oncology (2020)
- Royal College of Physicians & Surgeons of CANADA, Obstetrics & Gynecology (2018)
- Yale New Haven Healthy Lawrence and Memorial Hospital (2023 - Present): Physician Advisory Council
- Frontiers in Oncology (2023 - Present): Editor
- Connecticut Department of Health (2023 - Present): CT Cancer Partnership's HPV workgroup
- Insider (2022 - Present): https://www.insider.com/uterine-cancer-researchers-obgyn-want-more-data-on-hair-straightener-chemicals-2022-12
- Department of OBGYN Diversity, Equity and Inclusion, Research and Recruitment (2022 - Present): Co-Chair
- Yale University School of Medicine (2022 - Present): Medical Education Committee
- Medical Education Committee (2022 - Present): Member
- Diversity, Equity and Inclusion Committee of the Society of Gynecologic Oncology (2021 - Present): Committee Member
- Society of Gynecologic Oncologists of Canada (2017 - Present): Member
- American Association of Gynecologic Laparoscopists (2014 - Present): Member
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Britton M, Izampuye E, Clark M, Ornstein R, Nunez-Smith M, Wright J, Xu X. Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study. Gynecologic Oncology 2024, 191: 67-73. PMID: 39362045, DOI: 10.1016/j.ygyno.2024.09.010.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. DOI: 10.1038/s44276-024-00067-5.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLOS ONE 2023, 18: e0289692. PMID: 37682914, PMCID: PMC10490884, DOI: 10.1371/journal.pone.0289692.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- Maurer J, Ramani S, Xu B, Gallousis S, Clark M, Andikyan V. Delayed presentation of placenta accreta following a first‐trimester medical abortion. Clinical Case Reports 2023, 11: e7849. PMID: 37636882, PMCID: PMC10457480, DOI: 10.1002/ccr3.7849.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- Sullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.
- Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Ramani S, Hartnett J, Karki S, Gallousis S, Clark M, Andikyan V. Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2023, 27: e2023.00021. PMID: 37663433, PMCID: PMC10473183, DOI: 10.4293/jsls.2023.00021.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology 2022, 167: 417-422. PMID: 37191644, DOI: 10.1016/j.ygyno.2022.10.014.
- Piedimonte S, Kim S, Clark M, Lheureux S, May T, Bernardini M, Atenafu E. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190). Gynecologic Oncology 2022, 166: s109. DOI: 10.1016/s0090-8258(22)01417-2.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
- Clark M, Tchrakian N, Clarke B, Metser U, Bouchard-Fortier G. Placenta increta mimicking placental site trophoblastic tumor. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2021, 31: 1481-1485. PMID: 34725244, DOI: 10.1136/ijgc-2021-002988.
- Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Preventive Medicine 2021, 150: 106641. PMID: 34048822, DOI: 10.1016/j.ypmed.2021.106641.
- Irshaid L, Clark M, Fadare O, Finberg KE, Parkash V. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review. International Journal Of Gynecological Pathology 2021, 41: 258-267. PMID: 33990091, DOI: 10.1097/pgp.0000000000000792.
- Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
- Clark M, Jembere N, Wang L, Kupets R. Survival of Older Women With Cervical Cancer Based on Screening History. Journal Of Lower Genital Tract Disease 2021, 25: 9-14. PMID: 33347044, DOI: 10.1097/lgt.0000000000000582.
- The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital wartsClark M, Jembere N, Kupets R. The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital warts. Gynecologic Oncology 2020, 159: 173. DOI: 10.1016/j.ygyno.2020.05.257.
- Clark M, Al houssan L, Liu Z, Bernardini M. Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer. Gynecologic Oncology 2019, 154: 261. DOI: 10.1016/j.ygyno.2019.04.603.
- Clark M, Kollara A, May T, Brown T. Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperature. Gynecologic Oncology 2019, 154: 55-56. DOI: 10.1016/j.ygyno.2019.04.133.
- Clark M, Lee A, Kupets R. Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing? Journal Of Obstetrics And Gynaecology Canada 2019, 41: 1410-1415. PMID: 30803876, DOI: 10.1016/j.jogc.2018.11.034.
- Seifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: e2019.00021. PMID: 31285650, PMCID: PMC6596444, DOI: 10.4293/jsls.2019.00021.
- Seifi F, Clark M, Menderes G, Silasi D, Azodi M. 500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy? Journal Of Minimally Invasive Gynecology 2018, 25: s175. DOI: 10.1016/j.jmig.2018.09.512.
- Clark M, Seifi F, Parkash V, Silasi D, Azodi M. Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy? Gynecologic Oncology 2018, 149: 93. DOI: 10.1016/j.ygyno.2018.04.213.
- Clark M, Lee Y, Xu W, Brown T, May T. Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer? Gynecologic Oncology 2018, 149: 92. DOI: 10.1016/j.ygyno.2018.04.210.
- Lee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.
- Lennox G, Clark M, Zigras T, Rouzbahman M, Han G, Bernardini M, Gien L. Clinical stage II endometrial cancer: Is there a benefit to radical hysterectomy? Gynecologic Oncology 2018, 149: 103. DOI: 10.1016/j.ygyno.2018.04.239.
- Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reachClark M, Lee A, Kupets R. Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reach. Gynecologic Oncology 2018, 149: 126-127. DOI: 10.1016/j.ygyno.2018.04.292.
- Seifi F, Davis M, Clark M, Paraiso E, Azodi M. 563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2017, 24: s184-s185. DOI: 10.1016/j.jmig.2017.08.591.
- Seifi F, Clark M, Sami A, Azodi M. 519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction. Journal Of Minimally Invasive Gynecology 2017, 24: s183. DOI: 10.1016/j.jmig.2017.08.547.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Clark M, Menderes G, Azodi M, Finberg K, Canosa S, Parkash V. Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome. Gynecologic Oncology 2016, 141: 183-184. DOI: 10.1016/j.ygyno.2016.04.473.
- Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi D. Uterine Serous Carcinoma: Does surgical approach impact survival? Gynecologic Oncology 2015, 139: 592. DOI: 10.1016/j.ygyno.2015.09.045.
- Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA. Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? Journal Of Minimally Invasive Gynecology 2015, 22: s48-s49. PMID: 27679256, DOI: 10.1016/j.jmig.2015.08.134.
- Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M. Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma. Journal Of Minimally Invasive Gynecology 2015, 22: s59. PMID: 27679285, DOI: 10.1016/j.jmig.2015.08.157.
- Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian CystsClark M, Zigras T, Bayat L, Kashani S. Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian Cysts. Journal Of Minimally Invasive Gynecology 2015, 22: s150. PMID: 27678844, DOI: 10.1016/j.jmig.2015.08.547.
- Donat L, Clark M, Tower AM, Menderes G, Parkash V, Silasi DA, Azodi M. Transvaginal Morcellation. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2014.00255. PMID: 26005318, PMCID: PMC4432719, DOI: 10.4293/jsls.2014.00255.
- O’Sullivan R, Sauer C, Friedman P, Clark M, Menderes G. Rupture of the Unscarred Gravid Uterus: Case Series. Journal Of Medical Cases 2015, 6: 330-332. DOI: 10.14740/jmc2203w.
- Clark L, Clark M, Menderes G, Silasi D, Azodi M. Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2014, 21: s205. DOI: 10.1016/j.jmig.2014.08.658.
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Yale Cancer Center
- Yale Gynecologic OncologySmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
- Yale Gynecologic OncologyStamford Hospital1 Hospital PlazaStamford, CT 06902
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecologic OncologySmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
- Yale Gynecologic OncologyStamford Hospital1 Hospital PlazaStamford, CT 06902
- Yale Gynecologic OncologyBridgeport Hospital267 Grant StreetBridgeport, CT 06610